Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.

ABSTRACT:

Background

Plague is a high-consequence infectious disease with epidemic potential. Current treatment guidelines are based on weak evidence.

Methods

We enrolled persons (excluding pregnant persons) in Madagascar who had clinically suspected bubonic plague during 2020-2024. Using an open-label noninferiority design, we compared two treatments included in the national plague guidelines: oral ciprofloxacin for 10 days (ciprofloxacin monotherapy) or injectable aminoglycoside for 3 days followed by oral ciprofloxacin for 7 days (aminoglycoside-ciprofloxacin). The primary end point was treatment failure on day 11, with treatment failure defined as death, fever, secondary pneumonic plague, or alternative or prolonged plague treatment. To show noninferiority of ciprofloxacin monothe

SUBMITTER: Randremanana RV 

PROVIDER: S-EPMC7618094 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature